Preliminary Results From a Multidisciplinary University-Based Disease State Management Program Focused on Hypertension, Hyperlipidemia, and Diabetes

2011 ◽  
Vol 25 (2) ◽  
pp. 130-135 ◽  
Author(s):  
David R. Bright ◽  
Kelly R. Kroustos ◽  
Rhonda E. Thompson ◽  
Scott C. Swanson ◽  
Sara L. Terrell ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Clinical Outcomes ◽  
Exercise Physiology ◽  
Pressure Control ◽  
Management Program ◽  
Disease State ◽  
State Management ◽  
Disease State Management ◽  
Patients With Diabetes ◽  
Fitness Parameters

Objective: To describe the implementation and evaluation of a pilot multidisciplinary disease state management (DSM) program for diabetes, hypertension, and hyperlipidemia at a private, self-insured university (over 900 covered lives). Methods: Enrollees met with a pharmacist, nurse, exercise physiologist, and students in these disciplines to improve clinical outcomes and fitness parameters. Clinical values, quality of life, patient knowledge of disease states, and patient satisfaction were assessed. Results: Of the 20 patients in the pilot program, 17 completed 1 nursing and 2 pharmacist visits; 8 completed exercise physiology visits. At baseline, elevated blood pressure readings were observed in 64.7% (11 of 17) of patients, 20% of those with diabetes (1 of 5) had an elevated hemoglobin A1c value (HbA1c), and 82.4% (14 of 17) had a cholesterol value that was not at goal. At least 1 medication-related problem was observed in 16 patients (94.1%). At 3 months, all patients with diabetes achieved HbA1c levels at or below 7%, 4 patients attained blood pressure control, and 1 achieved normal cholesterol readings. Patients characterized participation in the program as valuable and convenient. Conclusions: Patients involved in the multidisciplinary DSM showed improved clinical outcomes after 3 months. Ongoing analysis of patient outcomes will determine the long-term effectiveness of the DSM.

Effect of Visit Frequency of Pharmacist-Led Diabetes Medication Management Program

2020 ◽  
pp. 089719002094868
Author(s):  
Amy Frederick ◽  
Joyce Juan ◽  
Delaney Ivy ◽  
Yolanda Munoz Maldonado
Keyword(s):  
Blood Pressure ◽  
Hemoglobin A1c ◽  
Medication Management ◽  
Retrospective Chart Review ◽  
Management Program ◽  
P Value ◽  
State Management ◽  
Disease State Management ◽  
Visit Frequency ◽  
Patients With Diabetes

Background: Pharmacists have a positive effect on clinical outcomes in chronic disease state management, however, few studies have evaluated the effect that frequency of visits may have on diabetes biomarkers such as hemoglobin A1c and blood pressure readings. Methods: Under the medication management program (MMP), patients with diabetes were seen monthly by pharmacists until early 2015, when time between visits was increased to every 3 months. A retrospective chart review was conducted to evaluate the primary outcome of the percent change in hemoglobin A1c and blood pressure after the change in visit frequency. Results: In the 303 patients enrolled, no statistical difference existed between the pre and post average A1c (p-value = 0.10). The intermediate average A1c was statistically lower from the preintervention mean A1c (p-value = 0.001) but not from the postintervention mean A1c (p-value = 0.30). No statistical differences were seen between systolic blood pressure and diastolic blood pressure. Conclusion: Patients who have been seen by a clinical pharmacist more frequently (every month or every other month) for several years may be able to maintain their reduction in A1c with less-frequent visits (every 3 to 6 months).

scholarly journals Advanced Practice Internship: Experiential Learning in a Drug Use and Disease State Management Program

2006 ◽  
Vol 70 (3) ◽  
pp. 68 ◽  
Author(s):  
Susan J. Skledar ◽  
Teresa P. McKaveney ◽  
Charles O. Ward ◽  
Colleen M. Culley ◽  
Kelly C. Ervin ◽  
...  
Keyword(s):  
Drug Use ◽  
Experiential Learning ◽  
Management Program ◽  
Disease State ◽  
Advanced Practice ◽  
State Management ◽  
Disease State Management

Evaluation of a disease state management guideline for urinary tract infection

2016 ◽  
Vol 47 (6) ◽  
pp. 451-456 ◽  
Author(s):  
Monika T. Zmarlicka ◽  
Sophia M. Cardwell ◽  
Jared L. Crandon ◽  
David P. Nicolau ◽  
Mitchell H. McClure ◽  
...  
Keyword(s):  
Urinary Tract Infection ◽  
Urinary Tract ◽  
Tract Infection ◽  
Disease State ◽  
Management Guideline ◽  
State Management ◽  
Disease State Management

Abstract 086: Secondary Prevention of Cardiovascular Disease in Patients With Type 2 Diabetes: International Insights From the TECOS Trial

2017 ◽  
Vol 10 (suppl_3) ◽  
Author(s):  
Neha J Pagidipati ◽  
Ann Marie Navar ◽  
Karen S Pieper ◽  
Jennifer B Green ◽  
M. A Bethel ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Cardiovascular Disease ◽  
Latin America ◽  
North America ◽  
Secondary Prevention ◽  
Eastern Europe ◽  
Statin Therapy ◽  
Smoking Status ◽  
Pressure Control ◽  
Patients With Diabetes

Background: Intensive risk factor modification significantly improves outcomes for patients with diabetes and cardiovascular disease (CVD). However, the degree to which secondary prevention treatment targets are achieved in international clinical practice is unknown. Methods: Attainment of 5 secondary prevention targets—aspirin use, lipid control (low-density lipoprotein cholesterol (LDL-C) <70 mg/dL or statin therapy), blood pressure control (<140 mmHg systolic, <90 mmHg diastolic), angiotensin-converting enzyme inhibitor or angiotensin receptor blocker use, and non-smoking status—was evaluated among 14,671 patients from 38 countries with diabetes and known CVD at entry into TECOS. Logistic regression was used to evaluate the association between individual and regional factors and target achievement. Results: Overall, 29.9% of patients with diabetes and CVD had all 5 secondary prevention measures at target. North America had the highest proportion (41.2%), whereas Western Europe, Eastern Europe, and Latin America had proportions of approximately 25%. The likelihood of having individual prevention components at target also varied by region: compared with North America, individuals in all other regions were less likely to have blood pressure at goal, and individuals in Eastern Europe and Latin America were less likely to have LDL-C at target or to be on statin therapy (see Figure). Overall, blood pressure control (57.9%) had the lowest overall attainment while non-smoking status had the highest (89%). Conclusions: On a global scale, significant opportunities exist to improve the quality of cardiovascular secondary prevention care among patients with diabetes and CVD, which in turn could lead to reduced risk of downstream cardiovascular events.

scholarly journals Impact of the COVID-19 Pandemic on Glycemic Control and Blood Pressure Control in Patients with Diabetes in Japan

2022 ◽  
Vol 61 (1) ◽  
pp. 37-48
Author(s):  
Keisuke Endo ◽  
Takayuki Miki ◽  
Takahito Itoh ◽  
Hirofumi Kubo ◽  
Ryosuke Ito ◽  
...  
Keyword(s):  
Blood Pressure ◽  
Glycemic Control ◽  
Blood Pressure Control ◽  
Pressure Control ◽  
Patients With Diabetes
Sign in / Sign up

Export Citation Format

Share Document